COMMUNIQUÉS West-GlobeNewswire

-
Aptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AML
09/12/2024 -
CRISPR Therapeutics Presents Data at the 2024 American Society of Hematology (ASH) Annual Meeting
09/12/2024 -
Editas Medicine Reports Updated Clinical Data from the RUBY Trial of Reni-cel in Patients with Severe Sickle Cell Disease at the American Society of Hematology (ASH) Annual Meeting
09/12/2024 -
Ipsen - November 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
09/12/2024 -
Ipsen - Novembre 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
09/12/2024 -
Dr. Merit Cudkowicz, Renowned ALS Expert at Massachusetts General Hospital (MGH), Joins Klotho Neurosciences’ Scientific Advisory Board
09/12/2024 -
Novo Nordisk A/S - share repurchase programme
09/12/2024 -
Monica Lewinsky Visits Agnivesh Agarwal’s Primeks Medical in Istanbul
09/12/2024 -
COVID Vaccines’ Genetic Mechanism Inadequately Tested, according to Journal of American Physicians and Surgeons (AAPS)
09/12/2024 -
Immix Biopharma to Host Conference Call for Investors, Analysts and Members of the Media
09/12/2024 -
Artelo Biosciences Announces Presentation of Phase 1 Data with ART27.13 in Cancer-Related Anorexia
09/12/2024 -
Healthcare Integrated Technologies welcomes former Google Executive & Head of Sales Enablement, Theo Davies as Chief Commercial Officer
09/12/2024 -
UPDATE: MEDIROM Healthcare Technologies Has Received Orders for Over 25,000 MOTHER Bracelet Units
09/12/2024 -
T2 Biosystems Announces Plans to License its Proprietary Technology to Expand its Leadership in Direct-From-Whole-Blood Detection of Sepsis-Causing Pathogens
09/12/2024 -
Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m
08/12/2024 -
Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
08/12/2024 -
TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma
08/12/2024 -
C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader
08/12/2024 -
Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
08/12/2024
Pages